# Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

> **NCT00881816** · PHASE1 · UNKNOWN · sponsor: **Nanjing Sike Pharmaceutical Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Advanced Gastric Carcinoma

## Interventions

- **DRUG:** Liposomal paclitaxel plus capecitabine

## Key facts

- **NCT ID:** NCT00881816
- **Lead sponsor:** Nanjing Sike Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2009-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881816, "Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00881816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*